Bacteria don't invade quietly. The moment a triacylated lipopeptide from a mycobacterium, spirochete, or gram-positive organism reaches your innate immune cells, it should trigger a rapid response — but only if Toll-Like Receptor 1 (TLR1)¹¹ Toll-Like Receptor 1 (TLR1)
TLR1 is a pattern-recognition receptor that forms heterodimers with TLR2 to detect bacterial triacylated lipopeptides such as those from Mycobacterium tuberculosis and M. leprae has reached the cell surface. The rs5743618 I602S variant (c.2079T>G, historically labeled 1805T>G) disrupts a transmembrane trafficking motif at the boundary between TLR1's transmembrane and intracellular domains, trapping the receptor inside the cell rather than displaying it on the surface.

The evolutionary history of this variant is striking. The serine-602 (S) allele, which impairs TLR1 surface expression, shows clear signatures of positive selection²² clear signatures of positive selection
iHS and XP-EHH statistics in the 1000 Genomes populations in European populations and is found in approximately 75% of Europeans — making intact (isoleucine-602) TLR1 the minority form in Europe. The allele is far less common in African (~25%) and East Asian (~2%) populations, suggesting it was selected for in environments where dampening TLR1 signaling conferred a survival advantage, possibly by reducing immunopathology from chronic bacterial and mycobacterial exposure.

The Mechanism

TLR1 and TLR2 form obligate heterodimers to recognize bacterial triacylated lipopeptides (tri-acyl LP)³³ bacterial triacylated lipopeptides (tri-acyl LP)
lipoproteins with three fatty acid chains found on mycobacteria, borreliae, and gram-positive bacteria — structurally distinct from the diacylated lipopeptides recognized by TLR2/TLR6 heterodimers. When TLR1/TLR2 binds its ligand, the intracellular TIR domains recruit MAL and MyD88 and activate NF-κB, producing TNF-α, IL-6, IL-12, and other pro-inflammatory cytokines essential for bacterial killing.

The I602S substitution places a serine — a hydroxyl-bearing, polar amino acid — at position 602 in the transmembrane domain, where the hydrophobic isoleucine is required for proper folding and export. The result: TLR1 protein is produced normally but retained intracellularly⁴⁴ retained intracellularly
individuals homozygous for 602S completely lack cell-surface TLR1 while retaining normal intracellular TLR1 protein levels. Without surface expression, TLR1/TLR2 heterodimers cannot form efficiently, and NF-κB activation by triacylated lipopeptides is severely blunted⁵⁵ NF-κB activation by triacylated lipopeptides is severely blunted
whole-blood TNF-α production after Pam3CSK4 stimulation is markedly reduced in 602S homozygotes.

A key mechanistic nuance: this variant exclusively disrupts TLR1-dependent signaling. TLR2/TLR6 heterodimer signaling (recognizing diacylated lipopeptides) is unaffected. This means the immune system is selectively blunted for one arm of bacterial lipopeptide recognition while the other remains intact.

The Evidence

Leprosy provided the first strong human association. Johnson et al. (2007) showed the 602S allele protects against clinical leprosy⁶⁶ protects against clinical leprosy
OR 0.48 in Turkish case-control, with 602S homozygotes predominantly in the healthy control group. A larger Indian case-control replication across two cities (New Delhi and Kolkata) confirmed this with a combined P = 5.7×10⁻⁸, OR = 0.31⁷⁷ combined P = 5.7×10⁻⁸, OR = 0.31
one of the strongest associations ever reported for an innate immune variant and an infectious disease. The paradox: reduced TLR1 signaling protects against leprosy by limiting mycobacteria-driven tissue damage and the Th1 immunopathology that drives the severe lepromatous form.

Tuberculosis shows the inverse. When TLR1 is active (602I/A allele), it helps defend against mycobacteria. A Han Chinese pediatric study⁸⁸ Han Chinese pediatric study
206 TB cases and 201 healthy controls found the A (602I) allele associated with increased TB risk (OR 2.40, 95%CI 1.41–4.07, P = 0.0009). A separate Brazilian cohort (Amazonas state) found that heterozygous 1805TG individuals were overrepresented among multibacillary vs paucibacillary TB⁹⁹ heterozygous 1805TG individuals were overrepresented among multibacillary vs paucibacillary TB
OR 3.72 for multibacillary disease — consistent with heightened TLR1 signaling driving the granulomatous response and immune pathology of more severe disease. These findings are not entirely consistent across all meta-analyses, suggesting population-specific and disease-stage-specific effects.

Sepsis reveals an additional dimension. In the intensive care setting, the 602I (A allele) confers enhanced neutrophil priming by Pam3CSK4¹⁰¹⁰ neutrophil priming by Pam3CSK4
TLR2/1 agonist: elevated ROS generation, MAPK phosphorylation, integrin activation, and cytokine secretion. In a pediatric sepsis cohort, children homozygous for the 602I genotype had a prolonged PICU length of stay, suggesting that overly active TLR1-mediated neutrophil responses may amplify organ damage in sepsis.

Post-infectious Lyme arthritis is the most recently described association. A 2025 study found that patients with TLR1 1805GG (602I/602I)¹¹¹¹ TLR1 1805GG (602I/602I)
the AA genotype on plus strand were significantly overrepresented among patients who developed persistent post-infectious Lyme arthritis after antibiotic treatment. In PBMCs with this genotype, repeated Borrelia burgdorferi stimulation failed to induce innate immune tolerance — resulting in unabated cytokine production even after bacterial clearance — consistent with the sustained joint inflammation seen in this condition.

Practical Implications

This variant sits at a meaningful evolutionary trade-off: the 602S allele (reduced TLR1 surface expression) was positively selected in European populations — likely because a dampened TLR1/TLR2 response reduces immunopathology in chronic mycobacterial exposure. But this selection came with a cost: less effective early bacterial clearance in some infection contexts, particularly for individuals who are AA (602I/602I) or have one active copy (AC), who face an inverted risk landscape.

For users carrying the A allele (602I, full TLR1 surface expression): the practical significance depends heavily on exposure context. In low-leprosy environments, having intact TLR1 is generally an asset for bacterial defense. The Lyme arthritis finding deserves attention for those in tick-endemic regions.

For CC (602S/602S) users: TLR1 surface expression is absent, reducing bacterial triacylated lipopeptide recognition. In populations where leprosy and severe mycobacterial disease are rare, this is largely a neutral-to-protective state. Standard infection prevention measures apply.

Interactions

TLR1 forms obligate heterodimers with TLR2 (rs5743708) for triacylated lipopeptide recognition. The TLR2 R753Q variant independently impairs TLR2 signaling, and in a Colombian case-control study, the haplotype combining rs5743618, rs5743708 (TLR2 R753Q), and rs5743810 (TLR6 Ser249Pro) was associated with altered leprosy susceptibility — suggesting additive effects across the TLR1/2/6 trimer complex. Carriers of both TLR1 A allele (602I) and TLR2 A allele (753Q) would likely face compounded reductions in combined TLR1/TLR2 output via independent mechanisms.

TLR6 (rs5743810) pairs with TLR2 to recognize diacylated lipopeptides — the functional partner on the other side. TLR4 (rs4986790) handles gram-negative LPS independently. Innate immune profiling across TLR1, TLR2, TLR4, TLR6, and TLR9 variants provides the most complete picture of bacterial recognition capacity.

The FUT2 gene encodes fucosyltransferase 2¹¹ fucosyltransferase 2
An enzyme that adds fucose sugar residues to glycan chains on cell surfaces and in secreted mucus, an enzyme that determines one of the most fundamental divisions in human biology: whether you are a "secretor" or a "non-secretor." Secretors express ABO blood group antigens²² ABO blood group antigens
The same A, B, and H antigens that define your blood type (A, B, AB, O), but expressed on mucosal surfaces and in saliva, tears, breast milk, and intestinal mucus rather than just on red blood cells on their mucosal surfaces and in bodily fluids like saliva and intestinal mucus. Non-secretors do not.

A single G-to-A change at position 428 of the FUT2 coding sequence creates a premature stop codon (Trp143Ter), completely inactivating the enzyme. People with two copies of the A allele — about 20% of Europeans — produce no functional FUT2 and are non-secretors. This is one of the most pleiotropic³³ pleiotropic
Affecting multiple, seemingly unrelated traits from a single genetic variant common variants in the human genome, influencing gut microbiome composition, vitamin B12 metabolism, susceptibility to viral infections, and risk of autoimmune disease.

The Mechanism

FUT2 adds fucose⁴⁴ fucose
A six-carbon sugar (6-deoxy-L-galactose) that serves as a building block for complex sugar chains on cell surfaces to glycan structures on the intestinal epithelium and in mucosal secretions, creating the H antigen — the precursor to A and B blood group antigens. In secretors, these fucosylated glycans coat the gut lining and are shed into the intestinal lumen, where they serve two critical functions.

First, they act as attachment points for certain pathogens. Norovirus and rotavirus bind to H-type and Lewis blood group antigens on intestinal cells to initiate infection. Without these glycans, the viruses literally cannot gain a foothold. Second, the shed fucosylated glycans serve as a carbon source for beneficial gut bacteria, particularly Bifidobacterium⁵⁵ Bifidobacterium
A genus of beneficial bacteria that are among the first colonizers of the infant gut and remain important for intestinal health throughout life species, which have evolved specialized enzymes to harvest fucose from host glycans.

The W143X nonsense mutation truncates the FUT2 protein at amino acid 143 (of 332 total), eliminating the catalytic domain entirely. Heterozygous carriers (AG) retain secretor status because one functional copy produces sufficient enzyme, though possibly at somewhat reduced levels.

The Evidence

The landmark norovirus study⁶⁶ landmark norovirus study
Thorven M et al. A homozygous nonsense mutation (428G→A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J Virol, 2005 demonstrated that among 115 Swedish adults exposed to norovirus outbreaks, not a single non-secretor (AA genotype) developed symptomatic infection, while 49% of GG homozygotes and 51% of AG heterozygotes were affected. A 2021 meta-analysis of 20 studies⁷⁷ 2021 meta-analysis of 20 studies
Bustamante M et al. FUT2 and norovirus: a systematic review and meta-analysis confirmed that non-secretors are approximately 3 times more likely to remain uninfected during norovirus exposure.

For vitamin B12, a genome-wide association study⁸⁸ genome-wide association study
Hazra A et al. Common variants of FUT2 are associated with plasma vitamin B12 levels. Nat Genet, 2008 identified FUT2 as the strongest genetic determinant of plasma B12 levels (p = 5.36 x 10^-17). Paradoxically, non-secretors have 16-18% higher measured serum B12⁹⁹ 16-18% higher measured serum B12
Velkova A et al. The FUT2 secretor variant p.Trp154Ter influences serum vitamin B12 concentration via holo-haptocorrin. Hum Mol Genet, 2017. However, this elevation is in haptocorrin-bound B12¹⁰¹⁰ haptocorrin-bound B12
Haptocorrin (also called transcobalamin I) is a B12 carrier protein in blood that is not readily taken up by cells. It is distinct from transcobalamin II, which delivers B12 to tissues — a biologically inactive fraction — rather than in holotranscobalamin¹¹¹¹ holotranscobalamin
The portion of blood B12 bound to transcobalamin II, which is the only form that can be actively taken up by cells and used for metabolic reactions, the bioavailable form. This means standard total B12 blood tests may overestimate functional B12 status in non-secretors.

The Crohn's disease link¹²¹² Crohn's disease link
McGovern DPB et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet, 2010 was established through GWAS, with non-secretors showing increased susceptibility (OR ~1.64 for AA genotype). A separate study¹³¹³ separate study
Smyth DJ et al. FUT2 nonsecretor status links type 1 diabetes susceptibility and resistance to infection. Diabetes, 2011 found that the AA genotype also confers susceptibility to type 1 diabetes (OR 1.29, 95% CI 1.20-1.37, p = 4.3 x 10^-18). The proposed mechanism links altered gut microbiome composition to immune dysregulation.

The gut microbiome connection¹⁴¹⁴ gut microbiome connection
Wacklin P et al. Secretor genotype (FUT2 gene) is strongly associated with the composition of bifidobacteria in the human intestine. PLoS One, 2011 showed that non-secretors harbor significantly lower diversity and abundance of Bifidobacterium species. Without fucosylated glycans lining the gut, these beneficial bacteria lose a primary food source, potentially contributing to the gut dysbiosis that underlies the increased Crohn's and autoimmune risk.

Practical Implications

The effects of FUT2 secretor status are a striking example of evolutionary trade-offs. Non-secretors gain robust protection against norovirus (and likely rotavirus and some bacterial pathogens) at the cost of a less diverse gut microbiome and modestly increased risk of certain autoimmune conditions.

For non-secretors (AA), the most actionable implications involve gut health maintenance and vitamin B12 monitoring. Since standard serum B12 tests may be misleadingly normal, requesting a holotranscobalamin (active B12) or methylmalonic acid test provides a more accurate picture of functional B12 status. Supporting gut bifidobacterial populations through targeted probiotics and prebiotic fiber is also worth considering, given the reduced diversity seen in non-secretors.

For heterozygous carriers (AG), secretor function is preserved and no specific action is typically needed, though being aware of this variant's role in B12 metabolism can inform supplement choices.

Interactions

FUT2 secretor status interacts with ABO blood type. The A and B antigens are built on top of the H antigen that FUT2 creates — so non-secretors do not express A, B, or H antigens in their mucus regardless of their ABO blood type. This means ABO-mediated disease associations on mucosal surfaces (such as susceptibility to H. pylori) can be modified by FUT2 status.

The variant rs602662 (S258G) and rs492602 are in strong linkage disequilibrium with rs601338 and show similar associations with B12 levels and disease risk. In East Asian populations, a different FUT2 variant (rs1047781, A385T) is the primary determinant of secretor status, since the W143X variant is nearly absent in that population (allele frequency <0.2%).

ROS1 encodes a receptor tyrosine kinase — a membrane-spanning signalling protein that responds to extracellular cues by triggering intracellular phosphorylation cascades that govern cell growth, differentiation, and survival. Unlike its better-known oncogenic role in non-small cell lung cancer¹¹ non-small cell lung cancer
ROS1 gene fusions drive ~1–2% of NSCLC cases and are targeted by crizotinib, the germline missense variant rs619203 is a common population polymorphism affecting the kinase domain. The C allele substitutes cysteine for serine at position 2229 of the protein, a change that introduces a free thiol group in a region important for kinase regulation. This variant was first flagged in a 2005 multi-phase case-control study as one of four novel SNPs associated with myocardial infarction, but subsequent replication has been inconsistent across populations.

The Mechanism

ROS1 signals through receptor tyrosine kinase pathways²² receptor tyrosine kinase pathways
RTKs phosphorylate downstream targets including PI3K/AKT and RAS/MAPK cascades that regulate vascular smooth muscle proliferation, endothelial function, and inflammatory signalling. The Ser2229Cys substitution falls within the kinase domain of the protein. Serine at this position is a potential phosphorylation site, and its replacement by cysteine — which carries a reactive thiol side chain — could alter autophosphorylation dynamics, receptor activation threshold, or substrate specificity. Because ROS1 is expressed at low levels in cardiac and vascular tissue, the proposed mechanism is that subtle perturbations in RTK-mediated vascular signalling cumulatively influence atherothrombotic plaque vulnerability or endothelial inflammatory tone rather than causing a dramatic, easily measurable biochemical phenotype.

The Evidence

The association between rs619203 and cardiovascular risk originated with Shiffman et al. 2005³³ Shiffman et al. 2005
Shiffman D et al. Identification of four gene variants associated with myocardial infarction. Am J Hum Genet. 2005;77(4):596-605, who conducted three sequential case-control studies totalling approximately 1,345 MI cases and 1,843 controls. They reported an OR of 1.75 for individuals homozygous for two risk alleles compared to non-carriers, with consistent directional effects across the three study phases. This was a significant initial signal in the era before large-scale GWAS.

Subsequent replication has been mixed. A Japanese association study of 3,432 individuals found the G→C polymorphism (Cys2229Ser) significantly associated with atherothrombotic cerebral infarction⁴⁴ significantly associated with atherothrombotic cerebral infarction
Yamada Y et al. Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. Stroke. 2008;39(8):2211-8, extending the cardiovascular signal to stroke. A Siberian study of 200 MI patients and 420 controls also confirmed the association and noted a link between rs619203 genotype and fasting glucose levels, suggesting a metabolic component.

However, several European replication attempts have failed. A German study of 3,657 MI cases and 1,211 controls found no significant difference in allele frequencies between MI patients and controls⁵⁵ no significant difference in allele frequencies between MI patients and controls
Koch W et al. Variations of specific non-candidate genes and risk of myocardial infarction. Int J Cardiol. 2011;148(3):339-44 (p≥0.25). A Russian cohort of young MI patients (<45 years) also found no significant association. These failures to replicate suggest either population-specific effects or that the initial signal reflected linkage to a causal variant not directly captured by rs619203. The overall evidence base qualifies this as emerging — insufficient for clinical use but biologically plausible.

Practical Actions

For CC homozygotes — who carry two copies of the Cys2229 allele and represent about 6% of people globally — monitoring of cardiovascular risk factors makes sense given the available signal, even without definitive clinical-grade evidence. The C allele frequency is highest in Europeans (~26%) and lowest in Africans (~8%), meaning the risk population is predominantly of European or East Asian ancestry. Standard cardiovascular biomarkers (hs-CRP, LDL, Lp(a)) and blood pressure tracking provide the most actionable handles for this genotype while the scientific evidence matures.

Interactions

rs619203 was initially identified alongside three other MI-associated SNPs in the same discovery study, including variants near rs499818. In the Siberian replication cohort, the strongest independent MI predictors were rs1333049 (9p21 locus) and rs10757278 (also 9p21), both of which showed more robust replication than rs619203. The 9p21 locus variants are well-established MI risk factors, and their co-presence with rs619203 in studies may represent confounding or additive — rather than synergistic — effects.

The serotonin 2A receptor gene (HTR2A) encodes one of the brain's most important receptors for serotonin signaling¹¹ serotonin signaling
Serotonin (5-HT) is a neurotransmitter involved in mood regulation, sleep, appetite, and cognition. The 5-HT2A receptor is a primary target for many antidepressants and antipsychotics.. The rs6311 polymorphism sits in the promoter region of this gene, 1438 bases upstream of the transcription start site, where it influences how much receptor protein your cells produce. This variant has been extensively studied for its role in psychiatric medication response²² psychiatric medication response
Over 149 publications have investigated this SNP in relation to mental health conditions and treatment response, though results have been notably inconsistent for efficacy and more consistent for side effects.

The Mechanism

Rs6311 is a regulatory variant³³ regulatory variant
Located in the promoter/5' UTR region, this SNP affects transcriptional regulation rather than changing the protein sequence directly that modulates HTR2A gene expression. The variant is transcribed in minor isoforms of HTR2A mRNA, particularly those with an extended 5' untranslated region (UTR). Research shows the A allele associates with reduced expression⁴⁴ A allele associates with reduced expression
The variant "A" allele of rs6311 is associated with reduced expression of isoforms containing the extended 5' UTR of these extended UTR isoforms. The G allele, conversely, allows higher expression of the extended 5' UTR, which may increase translational efficiency and ultimately receptor density in the brain.

Rs6311 exists in near-perfect linkage disequilibrium⁵⁵ near-perfect linkage disequilibrium
Rs6311 and rs6313 are in near-perfect LD, located 1538 bases apart on chromosome 13, with 99.6-99.7% concordance between alleles with rs6313 (T102C), a synonymous coding variant. In most cases, the rs6311 G allele pairs with rs6313 C, and rs6311 A pairs with rs6313 T. This tight linkage makes it difficult to determine which variant drives observed effects, though functional studies suggest rs6311's regulatory location may be more mechanistically relevant.

The Evidence

The most robust and replicated finding for rs6311 concerns SSRI side effects rather than efficacy. A weighted average of three paroxetine studies⁶⁶ weighted average of three paroxetine studies
All three studies (total n = 237) found significantly increased incidence of adverse events in patients with the -1438GG genotype, with side effect rates increasing from 15% among A carriers to 42% among GG homozygotes (n=237 total) showed side effect rates of 15% among A allele carriers versus 42% among GG homozygotes when treated with paroxetine. Similar patterns have been observed with other SSRIs including citalopram and fluvoxamine, though these findings await replication in larger cohorts.

In a Malay population study⁷⁷ Malay population study
The GG genotype of HTR2A polymorphism has decreased odds for dizziness but increased odds for poor concentration, while GA genotype increases odds for excessive sweating, diarrhea, constipation and blurred vision, the GG genotype showed decreased odds for dizziness but increased odds for poor concentration, while the GA genotype increased odds for excessive sweating, diarrhea, constipation, and blurred vision on SSRI treatment. A 2019 study on sexual dysfunction⁸⁸ 2019 study on sexual dysfunction
The -1438A/G and 102T/C polymorphisms appear associated with sexual dysfunction induced by citalopram, with risk increasing with number of "risky" alleles found that sexual dysfunction risk from citalopram/sertraline increased with the number of "risky" alleles (G for rs6311, C for rs6313, L for 5-HTTLPR).

Evidence for treatment efficacy is considerably less consistent. A large Chinese study⁹⁹ large Chinese study
Study of 290 patients treated with SSRIs found no association between rs6311 and treatment response or remission (n=290) found no association with SSRI response or remission. The STAR*D study, one of the largest antidepressant trials, also found no significant association¹⁰¹⁰ also found no significant association
Neither rs6311 nor rs6313 showed significant association with treatment response or remission in the STAR*D study for rs6311 with citalopram efficacy. A 2020 meta-analysis¹¹¹¹ 2020 meta-analysis
Pooled analyses of 16 studies (1931 subjects) indicated significant association with higher response in dominant model for 1438A/G polymorphism (OR: 1.40, 95% CI: 1.12-1.76) of 42 studies found some evidence for improved response with the GG genotype, but noted results were highly dependent on individual studies and publication bias may be present.

Beyond antidepressant effects, rs6311 has been studied extensively in schizophrenia. A meta-analysis of 15 case-control studies¹²¹² meta-analysis of 15 case-control studies
The -1438A/G polymorphism was a risk factor for schizophrenia, especially in Caucasians, with odds ratios ranging from 1.12-1.20 depending on genetic model found the G allele associated with increased schizophrenia risk in Caucasian populations (OR 1.12-1.20 depending on genetic model), though not in East Asian populations, highlighting important ancestry-specific effects.

Practical Implications

If you carry the GG genotype and are prescribed an SSRI, the evidence suggests heightened vigilance for side effects is warranted. The increased side effect risk with GG is one of the more consistent pharmacogenetic findings in psychiatry, though it's important to note this reflects population averages — individual responses vary considerably. Work closely with your prescriber to monitor for common SSRI side effects including gastrointestinal disturbances, sexual dysfunction, sleep changes, and activation symptoms, especially during the first 4-6 weeks of treatment.

The inconsistent efficacy data means rs6311 shouldn't guide initial drug selection, but it may inform how aggressively to pursue alternative medications if side effects emerge. If you experience intolerable side effects on one SSRI, alternatives include trying a different SSRI class (as pharmacokinetic differences may matter more than pharmacodynamic 5-HT2A effects), considering SNRIs or other antidepressant classes, or exploring non-serotonergic options depending on your clinical presentation.

For AA genotype carriers, the lower side effect risk doesn't guarantee a problem-free experience — individual factors including dose, drug-drug interactions, and comorbidities matter enormously. The same caution applies to those with AG genotypes, who show intermediate risk in the available data.

Interactions

Rs6311 interacts closely with rs6313 due to their near-complete linkage disequilibrium. Any effects attributed to one variant likely reflect the haplotype they share. Rs7997012, another HTR2A intronic SNP, has been studied primarily for antidepressant efficacy (with more consistent results than rs6311) and may compound effects on treatment response when combined with rs6311/rs6313 variants. Rs6314 (His452Tyr), a missense variant in HTR2A, also shows linkage with rs6311 and has been associated with aggressive traits and treatment response.

Compound effects involving rs6311 AG or GG genotypes plus rs6313 and 5-HTTLPR variants appear to increase sexual dysfunction risk on SSRIs in a dose-dependent manner. A 2011 study¹³¹³ 2011 study
Interaction between rs7997012, rs6311 and gender explained 14% of variance in treatment response, suggesting rs6311 may not independently influence outcome but plays a role through interactions found the interaction between rs7997012, rs6311, and gender explained 14% of variance in treatment response, suggesting rs6311's effects may emerge primarily through interactions rather than independently.

VEGFA (Vascular Endothelial Growth Factor A) encodes the master regulator of angiogenesis¹¹ angiogenesis
The formation of new blood vessels from existing ones, essential for tissue growth and repair. While VEGFA is widely known for its role in wound healing and cancer biology, it plays a surprisingly important role in adipose tissue function. Fat tissue requires an extensive blood vessel network to function properly — and VEGFA determines how well vascularized your fat depots are.

The rs6905288 variant sits in an intronic regulatory region near VEGFA on chromosome 6. It was identified in one of the largest GWAS meta-analyses for fat distribution and shows one of the clearest examples of sexual dimorphism²² sexual dimorphism
The genetic effect on fat distribution is substantially stronger in women than in men in fat distribution genetics.

The Mechanism

Adipose tissue is one of the most highly vascularized organs in the body. When fat tissue expands, it needs new blood vessels to supply oxygen and nutrients. VEGF-A drives this process, and the balance of VEGF-A expression determines whether fat expansion is metabolically healthy or unhealthy³³ metabolically healthy or unhealthy
Well-vascularized fat tissue stores lipids safely; poorly vascularized fat becomes inflamed, fibrotic, and insulin resistant.

Research has shown dichotomous effects⁴⁴ dichotomous effects
VEGF-A can either improve or worsen adipose function depending on the level and timing of expression — moderate VEGF-A overexpression in white adipose tissue promotes healthy fat expansion with better vascularization and even a "beiging" effect (conversion toward metabolically active brown-like fat), while dysregulated VEGF-A signaling promotes pathological adipose expansion with inflammation and fibrosis.

The A allele at rs6905288 is associated with altered VEGFA regulatory activity that shifts fat distribution toward a central pattern and increases insulin resistance.

The Evidence

The Heid et al. 2010 meta-analysis⁵⁵ Heid et al. 2010 meta-analysis
Heid et al. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet, 2010 identified rs6905288 near VEGFA among 13 new loci for WHR in a meta-analysis of 32 GWAS studies comprising 77,167 participants with replication in 113,636 individuals. VEGFA was one of seven loci showing marked sexual dimorphism, with stronger effects in women.

In a metabolic phenotyping study of 6,039 Danes⁶⁶ metabolic phenotyping study of 6,039 Danes
Burgdorf et al. Association studies of novel obesity-related gene variants with quantitative metabolic phenotypes in a population-based sample of 6,039 Danish individuals. Diabetologia, 2012, female carriers of the VEGFA rs6905288 A allele showed insulin resistance with a 3.7% increase in HOMA-IR⁷⁷ HOMA-IR
Homeostatic Model Assessment for Insulin Resistance, a standard measure calculated from fasting glucose and insulin (P = 0.00036) and a 4.0% decrease in the Matsuda index⁸⁸ Matsuda index
A measure of whole-body insulin sensitivity derived from an oral glucose tolerance test (P = 2 x 10^-4).

The Shungin et al. 2015 study⁹⁹ Shungin et al. 2015 study
Shungin et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature, 2015 expanded the evidence across 224,459 individuals, confirming the VEGFA locus and specifically implicating angiogenesis as a pathway linking genetic variants to fat distribution. A subsequent Mendelian randomization analysis¹⁰¹⁰ Mendelian randomization analysis
Emdin et al. JAMA, 2017 demonstrated that WHR-raising variants are causally linked to type 2 diabetes (OR 1.77) and coronary heart disease (OR 1.46).

Practical Actions

The VEGFA variant's effect on adipose vascularization and insulin resistance suggests that supporting healthy angiogenesis in fat tissue may help mitigate the metabolic consequences. Nutrients and activities that promote healthy vascular function in adipose tissue may be particularly relevant for carriers.

Interactions

VEGFA rs6905288 interacts biologically with the VEGFA promoter variant rs2010963 (already in this database under fitness/body). While rs2010963 directly affects VEGF-A protein expression levels, rs6905288 influences the regulatory context in adipose tissue specifically. Carriers of risk alleles at both positions may have compounded effects on adipose vascularization. Additionally, the angiogenesis pathway intersects with the VEGFC variant rs11677611 in the lipedema category, since both vascular growth factors regulate the fluid and fat dynamics in adipose tissue through complementary mechanisms.

Your immune system is not just a fighting force — it is also a meticulous cleanup operation. Dead and damaged cells must be recognized and engulfed efficiently to prevent their contents from triggering inflammation. ELMO1 (Engulfment and Cell Motility 1) is a central coordinator of this process, working within the gut epithelium and phagocytic immune cells to sense bacteria, orchestrate cytoskeletal changes needed for cell engulfment, and regulate the inflammatory signals that follow. The rs6974491 variant lies deep in ELMO1's first intron and, while it does not change the protein sequence, it acts as an expression quantitative trait locus¹¹ expression quantitative trait locus
An eQTL is a DNA variant that affects how much of a protein is made, rather than the protein's structure; the same amount of damage can be done by reducing the amount of a protein as by impairing its function — a regulatory tuning knob that alters ELMO1 expression in thymic and peripheral immune tissues.

ELMO1 operates as part of a conserved complex with DOCK180, together activating the small GTPase Rac1²² small GTPase Rac1
Rac1 is a molecular switch that triggers the cytoskeletal rearrangements needed for a cell to extend its membrane around a target and engulf it — the physical machinery of phagocytosis. This Rac1 activation drives lamellipodia formation, enabling immune cells to migrate toward signals of tissue damage and to physically engulf apoptotic cells and invading bacteria. When ELMO1 function is disrupted, cells cannot reliably complete this engulfment step — leaving cellular debris and bacteria uncleared, and triggering cascades that sustain inflammation long after the initial stimulus.

The Mechanism

rs6974491 sits at position c.78+7707 in ELMO1's first intron — approximately 7,700 nucleotides downstream of exon 1. ELMO1 is transcribed from the minus (antisense) strand³³ minus (antisense) strand
The minus strand runs in the opposite direction to the plus strand used as the genomic coordinate reference; genome files report plus-strand alleles, so G is the reference base and A is the risk allele at this position on chromosome 7, so the transcript notation is C>T while the genome file (plus-strand) reports G>A.

The A allele (plus strand) functions as an intronic regulatory variant influencing ELMO1 expression levels. An eQTL study in 42 thymic tissue samples⁴⁴ An eQTL study in 42 thymic tissue samples
Amundsen et al. examined 24 chromosomal regions carrying celiac disease SNPs for effects on thymic gene expression, identifying rs6974491-ELMO1 among nine probe-SNP pairs that replicated across both thymus and peripheral blood mononuclear cells demonstrated that rs6974491 consistently modulates ELMO1 expression in immune-relevant tissues — the thymus (where T cells are educated to distinguish self from non-self) and PBMCs (the primary immune effectors in blood).

The downstream consequence operates through two converging pathways. In gut epithelial cells, ELMO1 facilitates bacterial internalization and MCP-1 secretion⁵⁵ bacterial internalization and MCP-1 secretion
MCP-1 (monocyte chemoattractant protein 1) recruits circulating monocytes to sites of infection; its dysregulation either fails to clear pathogens or sustains excessive recruitment that drives chronic inflammation. In chronic inflammation, ELMO1 also regulates intestinal cellular senescence: ELMO1 stabilizes SIRT1 deacetylase activity, which prevents hyperacetylation of NF-κB's p65 subunit and the cellular senescence cascade that drives IBD-associated fibrosis⁶⁶ IBD-associated fibrosis. Reduced ELMO1 expression from the A allele may therefore impair both bacterial clearance and the brake on NF-κB-mediated chronic inflammation.

ELMO1 also interacts directly with NOD2⁷⁷ NOD2
NOD2 is an intracellular pattern recognition receptor that detects bacterial muramyl dipeptide — loss-of-function NOD2 mutations are among the strongest known Crohn's disease risk factors, binding through its C-terminal region to the NOD2 leucine-rich repeat domain. This physical interaction places ELMO1 in the same innate immune sensing circuit as the most established Crohn's disease risk gene.

The Evidence

The primary evidence for rs6974491's clinical relevance comes from multiple independent GWAS streams. The Dubois et al. 2010 celiac disease GWAS⁸⁸ Dubois et al. 2010 celiac disease GWAS
4,533 celiac cases and 10,750 controls; the study identified 13 new genome-wide-significant loci with ELMO1 among genes functionally relevant to the identified regions established rs6974491 as a celiac disease susceptibility signal (P < 5×10⁻⁸, OR ~1.25, 95% CI 1.16–1.36 per A allele). Notably, the study found that 52% of the identified celiac loci had variants correlated with cis-gene expression, consistent with rs6974491's eQTL mechanism.

The Mells et al. 2011 primary biliary cirrhosis GWAS⁹⁹ Mells et al. 2011 primary biliary cirrhosis GWAS
1,840 PBC cases and 5,163 UK population controls; 12 new susceptibility loci identified independently identified rs6974491 among susceptibility loci for a separate autoimmune condition — primary biliary cholangitis (PBC), an autoimmune liver disease caused by destruction of intrahepatic bile ducts. The replication of the same variant across celiac disease and PBC underscores that rs6974491 likely affects a shared mechanism of immune self-tolerance rather than organ-specific pathology.

The Parmar et al. 2012 IBD meta-analysis¹⁰¹⁰ Parmar et al. 2012 IBD meta-analysis
699 Finnish IBD patients and 2,482 controls, with Swedish UC replication; 45 genetic markers tested for celiac disease-IBD overlap found particularly strong effects in pediatric ulcerative colitis (OR 2.20, P=0.0002) and familial UC (OR 1.73, P=0.00052) — suggesting that the variant's impact on immune regulation is most visible in early-onset and familial disease forms, where genetic effects are proportionally larger.

The 2023 trans-ancestry Bayesian meta-analysis¹¹¹¹ 2023 trans-ancestry Bayesian meta-analysis
43,324 IBD cases and 57,206 controls across European, East Asian, and African American cohorts using MANTRA Bayesian analysis confirmed ELMO1 as an IBD risk locus across multiple ancestries, though the ELMO1 A allele frequency is extremely low in East Asian populations (< 0.5%), making European-ancestry findings the primary evidence base. The East Asian rarity of the A allele is notable — it makes the allele's disease associations almost exclusively a European-population story.

Practical Actions

The A allele modestly increases risk for gluten-triggered gut inflammation, IBD, and autoimmune conditions involving disrupted mucosal immunity. For GG carriers — the vast majority of the population — ELMO1 function is intact by default. For carriers of one or two A alleles, the most actionable implications concern early symptom recognition in celiac disease and IBD, and supporting the gut mucosal immune environment through specific dietary approaches.

Interactions

ELMO1 interacts directly with NOD2 (rs2066844, rs2066845, rs2066847 — common Crohn's disease variants); ELMO1 binds the NOD2 LRR domain and amplifies its bacterial sensing response. Carriers of both rs6974491-A and NOD2 loss-of-function alleles may have a compounded impairment in bacterial muramyl dipeptide sensing and clearance. Additionally, ELMO1 cooperates with DOCK180 (encoded by DOCK1) through direct physical interaction — the ELMO1/DOCK180 GEF complex is the upstream activator of Rac1, so variants affecting ELMO1 expression may compound with DOCK180 functional variants.

While rs7498665 (SH2B1 Thr484Ala) alters the structure of the SH2B1 protein, rs7359397 acts at an earlier level — it controls how much SH2B1 protein the cell makes in the first place. Located approximately 500 base pairs downstream of SH2B1 on chromosome 16, this variant sits within a CpG dinucleotide¹¹ CpG dinucleotide
A cytosine-guanine pair that is a common target for DNA methylation, which silences nearby genes when heavily methylated. The T allele creates an allele-specific methylation pattern that suppresses SH2B1 promoter activity²² suppresses SH2B1 promoter activity
When the downstream CpG region is hypermethylated, transcriptional repressors recognize the modified DNA and reduce SH2B1 mRNA output, meaning less adaptor protein available to amplify leptin and insulin receptor signals, reducing the cell's capacity to amplify both leptin and insulin receptor signals downstream of JAK2.

This variant is notably common in European populations — about 42% of Europeans carry the T allele — and has been linked specifically to NAFLD severity, insulin resistance, and differential responses to dietary interventions.

The Mechanism

SH2B1 functions as a master amplifier of JAK2 signaling. When leptin binds its receptor on hypothalamic neurons, JAK2 autophosphorylates and SH2B1 binds to phospho-JAK2 via its SH2 domain³³ SH2 domain
Src Homology 2 domain — a protein module that binds to specific phosphorylated tyrosine residues on activated kinases, dramatically increasing JAK2's catalytic activity and extending the signal through STAT3 to downstream appetite-suppressing genes. Less SH2B1 protein (due to rs7359397-driven hypermethylation) means less JAK2 amplification, blunted STAT3 phosphorylation, and reduced satiety signaling.

The CpG-SNP mechanism adds an epigenetic layer not present in coding variants: the T allele's methylation effects are potentially modifiable by dietary factors that influence one-carbon metabolism and global methylation status. This also explains the gene-diet interaction documented in intervention studies — T allele carriers respond differently to dietary composition changes that affect methyl-donor availability and insulin signaling.

The SH2B1 locus on chr16p11.2 is a dense LD block encompassing several genes (APOBR, SULT1A1, SULT1A2, TUFM); rs7359397 may partially tag effects at APOBR⁴⁴ APOBR
Apolipoprotein B receptor — involved in lipid uptake and metabolism, with its own associations with extreme obesity in fine-mapping studies. The primary phenotypic signal, however, is attributed to reduced SH2B1 expression.

The Evidence

The Mansego et al. 2015 CpG-SNP study⁵⁵ Mansego et al. 2015 CpG-SNP study
Mansego et al. SH2B1 CpG-SNP is associated with body weight reduction in obese subjects following a dietary restriction program. Annals of Nutrition and Metabolism, 2015 was the first to identify rs7359397 as a functional CpG-SNP, demonstrating that it showed the strongest association among seven obesity-related variants with weight, BMI, and truncal fat mass reduction during a caloric restriction program. The allele-specific methylation data linked the T allele to altered SH2B1 expression.

Two targeted studies from the Spanish FLiO (Fatty Liver in Obesity) cohort established the NAFLD connection. The 2020 cross-sectional study⁶⁶ 2020 cross-sectional study
Perez-Diaz-Del-Campo et al. Association of the SH2B1 rs7359397 Gene Polymorphism with Steatosis Severity in Subjects with Obesity and Non-Alcoholic Fatty Liver Disease. Nutrients, 2020 genotyped 110 obese/overweight subjects and found T allele carriers had dramatically higher rates of advanced NAFLD (69.1% vs 44.4%, p=0.006), elevated HOMA-IR (p=0.001), higher fatty liver index (OR 2.91), and nearly eight-fold greater risk of progressing to non-alcoholic steatohepatitis (RRR 7.88). The 2021 intervention follow-up⁷⁷ 2021 intervention follow-up
Perez-Diaz-Del-Campo et al. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: FLiO Study. European Journal of Nutrition, 2021 found that, despite worse baseline status, T allele carriers achieved 44.3% greater liver fat reduction (p<0.001) on the energy-restricted intervention — suggesting higher dietary sensitivity as a double-edged trait.

The insulin resistance effects extend beyond liver disease. The MAGIC consortium meta-analysis⁸⁸ MAGIC consortium meta-analysis
Fall et al. The role of obesity-related genetic loci in insulin sensitivity. Diabetic Medicine, 2012 of 37,037 participants confirmed the SH2B1 rs7359397 association with HOMA-IR (P=3.9×10⁻³). Separately, a 5,641-person young adult cohort⁹⁹ 5,641-person young adult cohort
Lange et al. Evidence for Association between SH2B1 Gene Variants and Glycated Hemoglobin in Nondiabetic European American Young Adults. Annals of Human Genetics, 2016 found significant association with HbA1c (P=9.8×10⁻⁴) largely independent of BMI, indicating a metabolic effect that operates at least partly outside the obesity pathway.

Practical Actions

Because rs7359397 acts through epigenetic regulation of SH2B1 expression, T allele carriers are particularly responsive to dietary interventions. The FLiO studies demonstrate that energy restriction produces substantially greater liver fat reduction in T allele carriers — a rare example of a genetic variant that identifies who will respond best to dietary treatment. Practically, this means T allele carriers should not assume their worse NAFLD baseline translates to worse outcomes: the data suggest the opposite under active intervention.

Liver monitoring is specifically actionable here: T allele carriers face an elevated baseline risk of NAFLD progression to NASH (RRR 7.88), and periodic liver enzyme and ultrasound monitoring can detect this progression early, when intervention is most effective.

Omega-3 fatty acid supplementation is specifically relevant for T allele carriers in NAFLD: the FLiO intervention showed T allele carriers increased omega-3 intake during the intervention and achieved superior lipidomic improvements. Higher fiber intake also tracked with better outcomes in T allele carriers.

Interactions

rs7359397 and rs7498665 are both in SH2B1 but affect the gene at different levels — rs7359397 reduces SH2B1 protein quantity (expression regulation) while rs7498665 reduces SH2B1 protein quality (structural impairment). Carriers of both T and G risk alleles simultaneously face compounded SH2B1 impairment: less protein that also functions less efficiently. The two variants are in partial but not complete LD on chr16p11.2, so they can be inherited independently and co-occur in the same individual.

SH2B1 sits upstream of LEPR (rs1137101) in the leptin signaling cascade: SH2B1 amplifies JAK2 after the leptin receptor activates it. Carrying T at rs7359397 (reduced SH2B1 expression) while also carrying a suboptimal LEPR variant compounds impairment at two sequential steps in leptin signaling.

Your muscles have two main fuels: carbohydrates (glucose stored as glycogen) and fats (fatty acids stored in adipose tissue). During moderate or prolonged exercise — and especially during fasting — muscles shift toward fat as their primary energy source. To burn long-chain fatty acids (the dominant fat in your diet and your body), those fatty acid chains must first cross into the mitochondria, the cell's power plant. That transport step requires a molecular ferry called carnitine palmitoyltransferase 2 (CPT2)¹¹ carnitine palmitoyltransferase 2 (CPT2)
A 658-amino-acid enzyme embedded in the inner mitochondrial membrane that transfers long-chain acylcarnitines across the inner membrane into the mitochondrial matrix, where β-oxidation then dismantles them into acetyl-CoA for energy. Without CPT2, long-chain fatty acids pile up outside the mitochondria, and muscle cells are forced to rely almost entirely on glycogen — which runs out quickly during sustained activity.

The p.Ser113Leu variant (c.338C>T in the CPT2 coding sequence) is the single most common mutation causing myopathic CPT II deficiency. Two copies of this variant — one from each parent — produce an enzyme that unfolds under physiological stress, leaving muscles metabolically stranded during the activities that demand fat-burning the most.

The Mechanism

The serine-to-leucine substitution at amino acid position 113 lies in a conserved region of the mature CPT2 protein. Functional studies²² Functional studies
Motlagh et al. 2016, PMID 27123472 — recombinant S113L CPT2 shows markedly increased thermolability and reduced steady-state protein levels in both fibroblasts and transfected cells show that p.Ser113Leu does not abolish enzyme synthesis — the mutant protein is made at near-normal levels — but it is substantially less stable, degrading faster than wild-type CPT2 under conditions of metabolic stress. The result is a reduced steady-state amount of functional enzyme (roughly 25–40% of normal residual activity in some assays), particularly at elevated temperatures.

This thermolability explains a hallmark feature of myopathic CPT II deficiency: febrile illness is among the most potent triggers³³ febrile illness is among the most potent triggers
Body temperatures above 38–39°C further destabilize the already marginally stable S113L protein, acutely dropping residual enzyme activity below the threshold needed to sustain muscle energy metabolism. The three classic triggers — prolonged exercise, fever, and fasting — all share a common mechanism: they increase the muscle's demand for long-chain fat oxidation at precisely the moment the S113L enzyme is least able to deliver it.

The Evidence

The S113L mutation was first identified as the common CPT2 disease allele by Taroni et al. 1993⁴⁴ Taroni et al. 1993
Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nature Genetics, 1993, who found it in 56% of mutant CPT2 alleles across 8 unrelated pedigrees with familial recurrent myoglobinuria. Subsequent population studies in European cohorts have consistently found the T allele accounting for 60–90% of CPT II deficiency alleles in Caucasians.

The overall population carrier frequency of the T allele is approximately 0.15% in gnomAD v2.1 (393/282,834 alleles globally), with a higher frequency of ~0.75% in the Ashkenazi Jewish subpopulation. Homozygotes (TT) are exceptionally rare in the population database, consistent with the clinical rarity of the condition (estimated at 1 in several hundred thousand live births for the symptomatic myopathic form).

A systematic review by Ivin et al. 2020⁵⁵ Ivin et al. 2020
Rhabdomyolysis caused by carnitine palmitoyltransferase 2 deficiency: A case report and systematic review. Journal of the Intensive Care Society, 2020 documents the cardinal clinical presentations: recurrent episodes of rhabdomyolysis (muscle fiber breakdown detectable as markedly elevated serum creatine kinase) and myoglobinuria (dark urine from released myoglobin), frequently resulting in acute kidney injury if fluid intake is insufficient during an episode. Symptoms typically begin in adolescence or early adulthood, often triggered by sustained exercise (particularly endurance activities), prolonged fasting, cold exposure, infection with fever, or combinations thereof.

For treatment, the fibrate drug bezafibrate — a PPAR-alpha/delta agonist — was shown by Bonnefont et al. 2010⁶⁶ Bonnefont et al. 2010
Long-term follow-up of bezafibrate treatment in patients with myopathic CPT2 deficiency. Clin Pharmacol Ther, 2010 to increase skeletal muscle palmitoyl-CoA oxidation rates by 39–206% in 6 patients with CPT2 deficiency (including S113L homozygotes), by upregulating residual CPT2 mRNA and enzyme expression through PPAR-mediated transcription. Patients reported increased physical activity and decreased muscular pain. Bezafibrate is not currently available in the United States (it is available in Europe and Canada) — fenofibrate is an alternative fibrate with a similar mechanism.

Practical Implications

For homozygous TT carriers, management centers on reducing dependence on long-chain fat oxidation during exercise and illness. Key strategies recommended in clinical guidelines and reviews include:

• Avoid prolonged fasting. Fasting forces muscles to rely on fatty acid oxidation. Eating regular meals with carbohydrate content is the single most effective daily precaution.
• Eat carbohydrates before sustained exercise. Pre-loading with slow-release carbohydrates (complex carbohydrates 1–2 hours before exercise) tops up muscle glycogen and delays the shift to fat oxidation during activity.
• Keep exercise sessions shorter and higher-intensity. Brief, high-intensity exercise (glycolytic by nature) is better tolerated than prolonged moderate-intensity endurance activity (which demands fat oxidation). Walking 20 minutes is less likely to trigger a crisis than jogging for 90 minutes.
• Aggressive fever management. Promptly treating febrile illness with antipyretics and ensuring adequate carbohydrate and fluid intake during infection substantially reduces crisis risk.
• Discuss fibrate therapy with your neurologist. Bezafibrate or fenofibrate may improve enzyme expression and exercise tolerance.

Heterozygous CT carriers typically have one functional CPT2 allele and maintain sufficient enzyme activity to avoid clinical disease. At least 21 heterozygous carriers have been documented with muscle CPT activity at 39–45% of normal — mildly reduced but usually asymptomatic at rest. A subset develop mild symptoms with very prolonged exertion or concurrent illness; most carriers are unaffected.

Interactions

CPT2 deficiency is a single-gene recessive disorder. Clinical severity is determined primarily by the number of T alleles and whether the second allele (in compound heterozygotes) is a null mutation or a milder missense. Compound heterozygosity for S113L (c.338C>T) plus a second rarer CPT2 mutation is the second most common genotype for adult myopathic CPT II deficiency after S113L/S113L homozygosity. The severity of compound heterozygous states depends on the residual activity of the second allele — null variants produce more severe phenotypes than missense variants.

The condition interacts with CPT1 variants (rs113994098 — CPT1B gene) at the physiological level: CPT1 and CPT2 together form the carnitine shuttle system. Variants reducing CPT1 activity from the outer mitochondrial membrane side compound with CPT2 dysfunction from the inner membrane side, though clinical interaction data for specific combined genotypes are limited.

Uterine fibroids (leiomyomata) affect up to 70% of women by age 50 and are the leading indication for hysterectomy worldwide. Their growth depends on a fundamental imbalance: fibroid smooth muscle cells proliferate but resist dying. FOXO1 — forkhead box protein O1¹¹ forkhead box protein O1
a transcription factor that drives expression of pro-apoptotic genes including BIM, PUMA, and Fas ligand — is a central regulator of that life-or-death balance. An intronic variant in FOXO1, rs7986407, has emerged from multiple genome-wide association studies as a locus influencing both uterine leiomyoma risk and the timing of natural menopause, two phenotypes that converge on estrogen exposure duration and uterine smooth muscle cell biology.

The Mechanism

Under normal conditions, FOXO1 translocates to the nucleus and transcribes genes that initiate programmed cell death — a key brake on abnormal cell accumulation. In leiomyoma cells, however, progestins (which drive fibroid growth) rapidly activate the PI3K/AKT signaling cascade²² PI3K/AKT signaling cascade
a pro-survival kinase pathway that is constitutively elevated in many tumors. Activated AKT phosphorylates FOXO1 at Ser256, causing it to be sequestered in the cytoplasm where it cannot reach its target genes. The result: pro-death signals are silenced and fibroid cells survive and accumulate. This mechanism was directly demonstrated by Hoekstra et al. (2009), who showed that blocking AKT or forcing nuclear FOXO1 entry with Psammaplysene A restored apoptosis in leiomyoma cells³³ blocking AKT or forcing nuclear FOXO1 entry with Psammaplysene A restored apoptosis in leiomyoma cells
Hoekstra AV et al. J Clin Endocrinol Metab 2009.

The rs7986407 variant is intronic and does not alter the FOXO1 protein sequence. Its functional effect likely operates through regulatory mechanisms — altered splicing efficiency, changes in intronic enhancer activity, or linkage disequilibrium with regulatory variants in the FOXO1 locus — that may modulate FOXO1 expression levels or transcript stability in uterine smooth muscle cells. The precise molecular consequence of the G allele in this tissue remains an open research question.

FOXO1 also plays a broader role in reproductive physiology: in ovarian granulosa cells, FOXO1 and its close family member FOXO3 regulate follicular development and granulosa cell apoptosis. Selective deletion of both in mice caused complete infertility⁴⁴ caused complete infertility
Liu Z et al. Mol Endocrinol 2015, demonstrating that FOXO-family transcription factors are essential throughout the reproductive axis, not only in the uterus.

The Evidence

The locus around rs7986407 has been identified in multiple large-scale GWAS efforts. The GWAS Catalog reports two fibroid associations at this variant: one with OR 1.07 (95% CI 1.04–1.10; p = 7 × 10⁻⁸; risk allele G) from studies in European-ancestry women, and a second association in a larger meta-analysis (p = 2 × 10⁻¹³; beta 0.064) where the A allele direction diverges — reflecting the complexities of phenotypic stratification across studies. A third entry in the GWAS Catalog records an association with uterine leiomyoma specifically (OR 0.93 per A allele; p = 2 × 10⁻¹⁸), consistent with a protective role of the A allele on fibroid risk.

The same A allele is associated with later age at natural menopause⁵⁵ later age at natural menopause
later menopause means longer total estrogen exposure across the reproductive lifespan at genome-wide significance (p = 4 × 10⁻¹⁹), suggesting that the A allele promotes prolonged functional ovarian activity. The relationship between these two A-allele phenotypes (later menopause and reduced fibroid risk, or context-dependent fibroid association) likely reflects the complex role of estrogen timing in uterine tissue biology.

A case-control study of 737 UF patients and 451 controls⁶⁶ case-control study of 737 UF patients and 451 controls
Ponomareva et al. 2024 found rs7986407 appearing in multiple gene-gene interaction models alongside rs547025 (SIRT3), rs2456181 (ZNF346), rs7907606 (STN1/SLK), and rs72709458 (TERT) — suggesting that the fibroid risk associated with this locus may be amplified or modified by co-occurring variants in related pathways. The SIRT3 connection is biologically plausible: sirtuin-family deacetylases directly regulate FOXO1 nuclear localization and activity, as shown by the SIRT1–FOXO1 axis in granulosa cells⁷⁷ SIRT1–FOXO1 axis in granulosa cells
miR-181a promotes SIRT1 downregulation, FOXO1 acetylation, and granulosa cell apoptosis via this axis.

Practical Actions

For women carrying two G alleles at rs7986407, the evidence may suggest a modest but biologically grounded susceptibility to uterine fibroid development, potentially acting through reduced FOXO1-mediated apoptotic surveillance in uterine smooth muscle cells. The fibroid phenotype in GG women may be modulated by factors that influence AKT pathway activity — including progestin exposure from hormonal contraception and body composition, as adipose tissue is a source of both estrogens and progestins.

Early pelvic ultrasound surveillance is the most actionable monitoring step for GG carriers. If fibroids are identified, awareness of the AKT/FOXO1 pathway biology may be relevant to treatment considerations, particularly given ongoing research into AKT-targeted fibroid therapies.

Interactions

The gene-gene interaction data from Ponomareva et al. 2024 and 2025 suggests that rs7986407 FOXO1 interacts with rs547025 SIRT3 in the context of uterine fibroid risk. SIRT3 (sirtuin 3) is a mitochondrial deacetylase with known roles in oxidative stress resistance and cellular longevity signaling. In the 2024 study, rs547025 SIRT3 showed the strongest individual protective effect against fibroids (C allele OR 0.61), while rs7986407 FOXO1 appeared repeatedly across interaction models. The biological rationale is compelling: SIRT3-family deacetylases regulate FOXO-family transcription factor activity through deacetylation, and FOXO1 acetylation status determines whether it can enter the nucleus to trigger apoptosis. A dual variant carrier — with both reduced SIRT3 protective capacity and a FOXO1 allele associated with fibroid risk — may face a convergent impairment of apoptotic regulation in uterine smooth muscle cells. Proposed compound action: SIRT3 rs547025 + FOXO1 rs7986407 — women carrying GG at rs7986407 (FOXO1, elevated fibroid risk) combined with TT at rs547025 (SIRT3, reduced protective effect) may have a compounded impairment of the SIRT3-FOXO1 apoptotic axis in uterine smooth muscle; recommended action would be earlier pelvic surveillance and monitoring of fibroid-related symptoms (heavy menstrual bleeding, pelvic pressure), plus consideration of lifestyle and dietary factors shown to support mitochondrial SIRT3 activity such as time-restricted eating and resistance exercise.

The endothelial protein C receptor (EPCR, encoded by the PROCR gene on chromosome 20) is a transmembrane glycoprotein on vascular endothelial cells that serves as the essential docking station for protein C activation¹¹ protein C activation
protein C is a vitamin K-dependent anticoagulant zymogen; when bound to EPCR, it is activated 20-fold more efficiently by the thrombin-thrombomodulin complex on the endothelial surface. Once activated, protein C (as APC — activated protein C) inactivates clotting factors Va and VIIIa, shutting down thrombin generation and protecting vessels from inappropriate clot formation. EPCR also anchors APC for cytoprotective PAR1 signaling²² cytoprotective PAR1 signaling
protease-activated receptor 1 (PAR1) triggers anti-inflammatory and endothelial barrier-stabilizing responses when activated by APC bound to EPCR — a distinct pathway from the pro-thrombotic PAR1 activation triggered by thrombin.

The rs867186 (S219G) variant substitutes glycine for serine at position 219 in the extracellular ectodomain³³ ectodomain
the portion of a transmembrane protein exposed on the cell surface, which can be proteolytically cleaved and released into circulation as a soluble fragment of EPCR. This single amino acid change dramatically alters how tightly EPCR is held at the cell surface — with consequences for both coagulation and inflammation.

The Mechanism

The Ser→Gly substitution at position 219 sits within the stalk region of EPCR adjacent to the transmembrane domain, exactly where ADAM metalloprotease-10 (ADAM10) cleaves EPCR⁴⁴ ADAM metalloprotease-10 (ADAM10) cleaves EPCR
ADAM proteases are zinc-dependent enzymes that shed ectodomains of membrane proteins; the 219Gly variant loosens the local protein structure, making the cleavage site more accessible to release soluble EPCR (sEPCR) into the bloodstream.

GG homozygotes have four-fold higher circulating sEPCR levels compared to AA homozygotes⁵⁵ GG homozygotes have four-fold higher circulating sEPCR levels compared to AA homozygotes
Ireland et al. Atherosclerosis 2005 — in vitro transfection confirmed increased basal release from cells expressing 219Gly. This has two opposing effects:

Pro-thrombotic pathway: sEPCR competitively sequesters circulating protein C away from the surface-bound EPCR that would activate it. Despite higher plasma protein C levels (because less is being activated and consumed), the functional anticoagulant response is blunted — protein C circulates but cannot dock efficiently on endothelial cells to be activated. Simultaneously, FVII and downstream coagulation activation markers (FIXpep, FXpep, prothrombin F1+2) rise proportionally with Gly allele dose⁶⁶ Gly allele dose
FVII elevated 6.9% in AG carriers and 23.4% in GG carriers vs AA, with a co-proportional rise in activated coagulation markers; Ireland et al. ATVB 2009, indicating net procoagulant shift despite the elevated protein C.

Anti-inflammatory pathway: sEPCR and APC-sEPCR complexes attenuate leukocyte-endothelial adhesion and vascular inflammation — explaining the paradoxical lower coronary artery disease risk in G allele carriers⁷⁷ paradoxical lower coronary artery disease risk in G allele carriers
Stacey et al., Nature Communications 2022 — PROCR-219Gly simultaneously reduces CAD risk through anti-inflammatory EPCR signaling while raising VTE risk through the coagulation FVII arm. This cross-phenotype pleiotropy — where the same variant decreases one vascular endpoint while increasing another — illustrates why simple "pro-thrombotic" labels can be misleading.

The Evidence

The VTE risk from rs867186 is among the most replicated associations in venous thrombosis genetics.

A HuGE meta-analysis of 37,415 cases and 84,406 non-cases across 25 studies⁸⁸ HuGE meta-analysis of 37,415 cases and 84,406 non-cases across 25 studies
Dennis et al. Blood 2012 — random-effects model, additive genetic model found each additional G allele increases VTE odds by 22% (OR 1.22, 95% CI 1.11–1.33, P < 0.001). No association was found with arterial MI.

A prospective Swedish cohort of 28,794 subjects followed through 2018⁹⁹ prospective Swedish cohort of 28,794 subjects followed through 2018
Manderstedt et al. Thrombosis and Haemostasis 2022 — Malmö Diet and Cancer Study, exome sequencing found only GG homozygosity — not AG heterozygosity — reached significance, with an adjusted HR of 1.5 (95% CI 1.1–2.0). This recessive-at-the-clinical-threshold pattern aligns with the dose-response in coagulation markers.

A subsequent meta-analysis of 5,768 cases and 30,017 controls¹⁰¹⁰ meta-analysis of 5,768 cases and 30,017 controls
Pituk et al. Front Cardiovasc Med 2023 — pooled analysis including their own Hungarian case-control study quantified genotype-specific risk more precisely: dominant model OR 1.27 (95% CI 1.11–1.46), recessive model OR 1.60 (95% CI 1.26–2.04), and GG versus AA OR 1.64 (95% CI 1.28–2.09). The same study found a non-significant trend toward higher VTE recurrence risk (OR 1.72, 95% CI 0.95–3.13, p = 0.075) in G carriers — a signal that may be meaningful for anticoagulation duration decisions.

At the genome-wide level, Thibord et al. Circulation 2022¹¹¹¹ Thibord et al. Circulation 2022
cross-ancestry GWAS of up to 81,669 VTE cases from 30 studies in European, African, and Hispanic populations — confirmed PROCR as an independent VTE locus among 135 significant signals and the Ghouse et al. Nature Genetics 2023¹²¹² Ghouse et al. Nature Genetics 2023
genome-wide meta-analysis of 81,190 cases and 1,419,671 controls — 93 risk loci, with PROCR among replication-confirmed signals both confirmed PROCR as an independent VTE risk locus in the largest genetic studies of venous thromboembolism conducted to date.

Practical Actions

For AG heterozygotes (the most common risk genotype at ~17.5% prevalence), the absolute risk increase is modest and typically does not alter standard clinical management. The key implication is awareness: recognizing an elevated baseline risk enables informed decisions around high-risk exposures such as prolonged immobility, surgery, or estrogen-containing contraceptives.

For GG homozygotes (~1% prevalence), the risk increment is clinically more meaningful (HR ~1.5 for incident VTE, OR ~1.64 in meta-analysis). This genotype warrants factoring into thrombotic risk stratification, particularly after a first unprovoked VTE when deciding on anticoagulation duration. PROCR S219G does not carry standalone indication for prophylactic anticoagulation, but it strengthens the case for extended therapy in ambiguous clinical scenarios.

The anti-inflammatory pleiotropic effect (lower CAD risk) does not require intervention — it is a passive benefit of the shedding mechanism.

Interactions

Factor V Leiden (rs6025) and prothrombin G20210A (rs1799963) are the strongest known inherited thrombophilia variants. Combining rs867186 with either of these creates a substantially higher cumulative VTE risk than any single variant alone, as these operate through independent mechanisms — FVII/PROCR pathway versus thrombin generation and fibrin deposition. Any carrier of rs867186 GG who also carries factor V Leiden or prothrombin mutation should be evaluated by a hematologist for thrombophilia risk stratification.

A second functional PROCR variant, Arg113Cys (rs146420040), was identified in the same Malmö cohort study and confers independent VTE risk (HR 1.3). The combination of both PROCR variants in the same individual has not been formally studied but would be expected to compound risk further.